Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Assessing Functionality and Benefits of Comprehensive Dose Volume Prescriptions: An International, Multi-Institutional, Treatment Planning Study in Spine Stereotactic Body Radiation Therapy.

Furuya T, Phua JH, Ruschin M, Tanaka H, Nihei K, Pinnaduwage D, Kumazaki Y, Nakayama M, Nishimura H, St-Hilaire J, Thibault I, Yat Harn DT, Ma L, Shikama N, Sahgal A, Karasawa K.

Pract Radiat Oncol. 2019 Jan;9(1):9-15. doi: 10.1016/j.prro.2018.05.006. Epub 2018 Nov 15.

PMID:
30611464
2.

Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.

Lee M, Tayyari F, Pinnaduwage D, Bayani J, Bartlett JMS, Mulligan AM, Bull SB, Andrulis IL.

BMC Cancer. 2018 Jul 20;18(1):750. doi: 10.1186/s12885-018-4653-6.

3.

Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers.

Forse CL, Pinnaduwage D, Bull SB, Mulligan AM, Andrulis IL.

Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):231-237. doi: 10.1097/PAI.0000000000000579.

PMID:
29553968
4.

Non-invasive optical spectroscopic monitoring of breast development during puberty.

Lilge L, Terry MB, Walter J, Pinnaduwage D, Glendon G, Hanna D, Tammemagi ML, Bradbury A, Buys S, Daly M, John EM, Knight JA, Andrulis IL.

Breast Cancer Res. 2017 Feb 6;19(1):12. doi: 10.1186/s13058-017-0805-x.

5.

Respiration-Induced Intraorgan Deformation of the Liver.

Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M.

Technol Cancer Res Treat. 2017 Jan 1:1533034616687193. doi: 10.1177/1533034616687193. [Epub ahead of print]

6.

Dosimetric characterization of hypofractionated Gamma Knife radiosurgery of large or complex brain tumors versus linear accelerator-based treatments.

Dong P, Pérez-Andújar A, Pinnaduwage D, Braunstein S, Theodosopoulos P, McDermott M, Sneed P, Ma L.

J Neurosurg. 2016 Dec;125(Suppl 1):97-103.

PMID:
27903198
7.

Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J.

Technol Cancer Res Treat. 2017 Apr;16(2):178-187. doi: 10.1177/1533034616649495. Epub 2016 Jul 8.

8.

An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation.

Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M 3rd, Gottschalk AR.

Technol Cancer Res Treat. 2017 Jun;16(3):267-275. doi: 10.1177/1533034616639729. Epub 2016 Mar 31.

9.

Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients.

McGuinness CM, Gottschalk AR, Lessard E, Nakamura JL, Pinnaduwage D, Pouliot J, Sims C, Descovich M.

J Appl Clin Med Phys. 2015 Sep 8;16(5):284–295. doi: 10.1120/jacmp.v16i5.5502.

10.

Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.

Mulligan AM, Pinnaduwage D, Tchatchou S, Bull SB, Andrulis IL.

Cancer Immunol Res. 2016 Jan;4(1):41-8. doi: 10.1158/2326-6066.CIR-15-0051. Epub 2015 Nov 6.

11.

Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer.

Forse CL, Agarwal S, Pinnaduwage D, Gertler F, Condeelis JS, Lin J, Xue X, Johung K, Mulligan AM, Rohan TE, Bull SB, Andrulis IL.

BMC Cancer. 2015 Jun 27;15:483. doi: 10.1186/s12885-015-1468-6.

12.

Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: insights from lung tumor patients treated with robotic radiosurgery.

Descovich M, McGuinness C, Kannarunimit D, Chen J, Pinnaduwage D, Pouliot J, Kased N, Gottschalk AR, Yom SS.

Med Phys. 2015 Mar;42(3):1280-7. doi: 10.1118/1.4907956.

PMID:
25735283
13.

Evaluating dosimetric differences in spine stereotactic body radiotherapy: An international multi-institutional treatment planning study.

Furuya T, Tanaka H, Ruschin M, Nihei K, Pinnaduwage D, Ma L, Sahgal A, Karasawa K.

J Radiosurg SBRT. 2015;3(4):307-314.

14.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Aug;146(3):657-67. doi: 10.1007/s10549-014-3050-3. Epub 2014 Jul 10.

PMID:
25007965
15.

Aberrant hedgehog signaling and clinical outcome in osteosarcoma.

Lo WW, Pinnaduwage D, Gokgoz N, Wunder JS, Andrulis IL.

Sarcoma. 2014;2014:261804. doi: 10.1155/2014/261804. Epub 2014 Mar 30.

16.

Impact of millimeter-level margins on peripheral normal brain sparing for gamma knife radiosurgery.

Ma L, Sahgal A, Larson DA, Pinnaduwage D, Fogh S, Barani I, Nakamura J, McDermott M, Sneed P.

Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):206-13. doi: 10.1016/j.ijrobp.2014.01.011.

PMID:
24725703
17.

Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.

Braunstein SE, Dionisio SA, Lometti MW, Pinnaduwage DS, Chuang CF, Yom SS, Gottschalk AR, Descovich M.

J Radiosurg SBRT. 2014;3(1):67-79.

18.

Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy.

Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS.

Technol Cancer Res Treat. 2015 Feb;14(1):49-60. doi: 10.7785/tcrt.2012.500394. Epub 2014 Nov 11.

PMID:
24325136
19.

Protein kinase C epsilon and genetic networks in osteosarcoma metastasis.

Goudarzi A, Gokgoz N, Gill M, Pinnaduwage D, Merico D, Wunder JS, Andrulis IL.

Cancers (Basel). 2013 Apr 8;5(2):372-403. doi: 10.3390/cancers5020372.

20.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL.

Mod Pathol. 2014 Apr;27(4):554-61. doi: 10.1038/modpathol.2013.153. Epub 2013 Sep 20.

21.

Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife.

Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M 3rd, Gottschalk AR.

J Appl Clin Med Phys. 2013 Sep 6;14(5):162-72. doi: 10.1120/jacmp.v14i5.4333.

22.

Whole-procedural radiological accuracy for delivering multi-session gamma knife radiosurgery with a relocatable frame system.

Ma L, Pinnaduwage D, McDermott M, Sneed PK.

Technol Cancer Res Treat. 2014 Oct;13(5):403-8. doi: 10.7785/tcrtexpress.2013.600259. Epub 2013 Aug 31.

23.

Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.

24.

A dosimetric evaluation of using a single treatment plan for multiple treatment fractions within a given applicator insertion in gynecologic brachytherapy.

Pinnaduwage DS, Cunha JA, Weinberg V, Krishnamurthy D, Nash M, Hsu IC, Pouliot J.

Brachytherapy. 2013 Sep-Oct;12(5):487-94. doi: 10.1016/j.brachy.2013.02.003. Epub 2013 Apr 11.

PMID:
23582467
25.

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.

Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.

26.

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer.

Forse CL, Yilmaz YE, Pinnaduwage D, O'Malley FP, Mulligan AM, Bull SB, Andrulis IL.

Breast Cancer Res Treat. 2013 Feb;137(3):709-19. doi: 10.1007/s10549-012-2392-y. Epub 2013 Jan 4.

PMID:
23288345
27.

Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.

Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.

28.

A technique for achieving submillimeter accuracy of volume-staged stereotactic radiosurgery.

Ma L, Fogh S, Gupta N, Hwang A, Pinnaduwage D, Nakamura J, Barani I, McDermott M, Sneed PK, Larson DA, Sahgal A.

J Radiosurg SBRT. 2012;2(1):11-17.

29.

Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma.

Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, Smith KA, Shapiro WR, Pinnaduwage DS, Coons SW, Nakaji P, Debbins J, Feuerstein BG, Baxter LC.

AJNR Am J Neuroradiol. 2012 Jan;33(1):69-76. doi: 10.3174/ajnr.A2743. Epub 2011 Nov 17.

30.

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Mulligan AM, Pinnaduwage D, Bane AL, Bull SB, O'Malley FP, Andrulis IL.

Cancer. 2011 Apr 1;117(7):1350-9. doi: 10.1002/cncr.25642. Epub 2010 Nov 2.

31.

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.

PMID:
21327470
32.

Transmission-ratio distortion in the Framingham Heart Study.

Paterson AD, Waggott D, Schillert A, Infante-Rivard C, Bull SB, Yoo YJ, Pinnaduwage D.

BMC Proc. 2009 Dec 15;3 Suppl 7:S51.

33.
34.

Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas.

Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE.

AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8. doi: 10.3174/ajnr.A1787. Epub 2009 Sep 12.

35.

A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.

Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14028-33. doi: 10.1073/pnas.0906796106. Epub 2009 Aug 10.

36.

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.

Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12903-8. doi: 10.1073/pnas.0810402106. Epub 2009 Jul 17.

37.

Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort.

Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL.

Clin Cancer Res. 2008 Jul 1;14(13):4168-74. doi: 10.1158/1078-0432.CCR-07-4543.

38.

Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2009 Sep;117(1):183-91. doi: 10.1007/s10549-008-0087-1. Epub 2008 Jun 18. Erratum in: Breast Cancer Res Treat. 2011 Feb;126(1):269. Reedijk, Michael [added]; Egan, Sean E [added].

39.

Application of bivariate mixed counting process models to genetic analysis of rheumatoid arthritis severity.

Sutradhar R, Pinnaduwage D, Bull SB.

BMC Proc. 2007;1 Suppl 1:S120. Epub 2007 Dec 18.

40.

Chlorine adsorption on Au(111): chlorine overlayer or surface chloride?

Gao W, Baker TA, Zhou L, Pinnaduwage DS, Kaxiras E, Friend CM.

J Am Chem Soc. 2008 Mar 19;130(11):3560-5. doi: 10.1021/ja077989a. Epub 2008 Feb 22.

PMID:
18290645
41.

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.

Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL.

Breast Cancer Res Treat. 2008 Oct;111(3):439-48. Epub 2007 Nov 8.

PMID:
17990101
42.

Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.

Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL.

Neoplasia. 2007 Oct;9(10):797-800.

43.

The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.

Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL.

BMC Cancer. 2007 May 19;7:85.

44.

Chlorine promotion of styrene epoxidation on Au(111).

Pinnaduwage DS, Zhou L, Gao W, Friend CM.

J Am Chem Soc. 2007 Feb 21;129(7):1872-3. Epub 2007 Jan 25. No abstract available.

PMID:
17253694
45.

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.

Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL.

Breast Cancer Res Treat. 2007 Nov;105(3):255-65. Epub 2007 Jan 13.

PMID:
17221157
46.

Efficient CO oxidation at low temperature on Au(111).

Min BK, Alemozafar AR, Pinnaduwage D, Deng X, Friend CM.

J Phys Chem B. 2006 Oct 12;110(40):19833-8.

PMID:
17020368
47.
48.

LAF-4 is aberrantly expressed in human breast cancer.

To MD, Faseruk SA, Gokgoz N, Pinnaduwage D, Done SJ, Andrulis IL.

Int J Cancer. 2005 Jul 1;115(4):568-74.

49.
50.

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL.

J Clin Oncol. 2004 Jan 1;22(1):86-96.

PMID:
14701769

Supplemental Content

Loading ...
Support Center